Addition, not subtraction — the core difference

A common first question when comparing these two pathways is whether the injection is simply a less invasive way of doing the same thing. The answer is no — and the difference is architectural, not incremental. Conventional cartilage surgery is subtractive: the surgeon debrides the joint bed, prepares a crater, dries the cartilage surface, and rebuilds upward from exposed bone under arthroscopic vision. The entire logic runs from the bottom up.

The ChondroFiller injection pathway runs in the opposite direction. Rather than removing tissue to create a clean base for repair, the injectable collagen scaffold is deposited directly over the worn articular surface, leaving everything around it untouched. As one formulation of the principle puts it: 'Where surgery subtracts — cutting away, digging out, exposing bone — this adds, and leaves everything else untouched.' No joint entry, no incision, no debridement. The collagen is placed under ultrasound guidance in an outpatient setting, and the joint's own environment triggers it to gel in situ. This is not a delivery shortcut to the same destination; it is a different clinical philosophy applied to the same problem.

How the material makes needle delivery possible

The short answer lies in chemistry. ChondroFiller Liquid (CE marked in 2013) is an acid-extracted Type I collagen that remains fluid under the neutral pH conditions used for injection and polymerises only once it contacts the joint's own environment. That phase change — liquid in the needle, gel in the defect — means the material can be placed precisely through a fine cannula under ultrasound guidance without any mechanical fixation or arthroscopic seating, both of which the pre-formed gel plug format requires.

Once gelled, the scaffold does something hyaluronic acid cannot: it stays. HA is a lubricant the joint clears within weeks; the collagen matrix is biologically integrable, meaning the body's own progenitor cells — drawn from the synovium and subchondral bone nearby — can migrate into it and begin to rebuild tissue over time. This process is described as acellular matrix-induced chondrogenesis: the scaffold contains no pre-seeded cells, but creates the structural conditions that recruit the patient's own, supporting the body's own repair processes rather than substituting for them. Ex vivo testing has confirmed this directly, showing a 2.4-fold increase in cell content within ChondroFiller-treated defects by day 14.

The bridge from biology to practice is delivery precision: how much material is placed matters as much as where it is placed. A 2025 wrist study (n=25) found that 0.2–0.3 mL through G20–21 cannulas produced statistically better cartilage quality scores than untreated controls — but only when applied flush to the defect surface. Overfilled defects developed fibrous tissue, making accurate, image-guided placement the critical technical discipline rather than an optional refinement.

What surgical cartilage repair actually requires

The surgical pathway for focal cartilage repair is a proven, well-established approach — but it carries specific prerequisites that not every patient can meet.

Arthroscopic cartilage surgery, whatever the technique, depends on a clearly defined focal defect surrounded by healthy cartilage at its borders. Microfracture penetrates the subchondral bone to draw in a marrow-derived repair response; osteochondral autograft transfer (OATS) transplants a cylindrical plug of bone and cartilage from a donor site; autologous chondrocyte implantation (ACI) harvests cells, cultures them in a laboratory, and implants them in a second procedure. All three share the same architectural assumption: a stable crater with sound edges to build against. Once damage becomes diffuse rather than focal, those edges disappear and each of these techniques loses its applicability.

Arthroscopic ChondroFiller implantation — using the pre-formed ChondroFiller Gel plug (CE mark 2012) — follows the same underlying logic. The defect bed must be mechanically debrided, the joint thoroughly dried, and the plug placed under direct arthroscopic vision. Theatre admission, joint entry, and post-arthroscopic rehabilitation are inherent to this route, not optional steps that can be omitted for convenience.

This is the clinical setting in which ChondroFiller Liquid (CE mark 2013), already described in the preceding section, represents a genuine departure: it is a separate CE-marked device built for an entirely different delivery route, not a needle-compatible reformulation of the same implant.

Who each pathway can treat — and who falls between them

Patient suitability determines which pathway is even available. As the preceding section established, surgical focal repair depends on a defect ringed by sound cartilage. When wear is diffuse rather than confined to a single crater, those conditions are absent — and that is precisely where the injection route becomes clinically relevant.

The injectable pathway does not depend on defect-edge integrity. Patients with early-to-moderate osteoarthritis, where damage has spread across a wider surface but has not yet reached the stage where joint replacement is the only realistic option, may be assessed for ChondroFiller injection when surgical repair is no longer applicable. This opens a window for a group who would otherwise sit in a gap between manageable focal repair and end-stage replacement.

The injection route has its own ceiling, however. A five-year hip cohort (n=26) found good or excellent results in 17 of 21 evaluable patients — but patients entering with moderate-to-severe pre-existing joint degeneration (Tönnis grade 2–3) consistently returned poor outcomes. Advanced disease places patients beyond what either pathway can reliably address before joint replacement becomes necessary.

One practical consideration also shapes recovery. Unlike a rigid surgical implant, ChondroFiller requires a period of protected weight-bearing after injection while the material completes gelation and stabilises in the defect. Biomechanical testing has confirmed that the material does not adequately shield opposing cartilage under early full weight-bearing; protected loading is therefore a clinical requirement rather than an optional precaution.

Eligibility is best understood as a continuum: a focal defect with intact surrounding cartilage widens the surgical options; diffuse early-to-moderate wear shifts the balance towards the injection pathway; advanced degeneration reaches beyond either.

What the clinical evidence shows

The most controlled comparison published to date is the Schneider 2016 randomised study — 13 patients receiving ChondroFiller Liquid against ten treated by microfracture. IKDC functional scores in the ChondroFiller group reached statistical significance at three months and remained improved at six and twelve months; MRI at 52 weeks showed progressive scaffold maturation and integration with the surrounding cartilage margins — a pattern consistent with ongoing biological remodelling rather than simple space-filling.

Longer follow-up comes from the hip arthroscopy cohort, which tracked patients with acetabular defects larger than 2 cm² for up to five years. Clinical scoring remained favourable in the majority of evaluable cases, and the series clarified where the treatment ceiling lies — addressed in the patient-selection discussion above.

Across a wider evidence base spanning knee, hip, ankle, and wrist applications, MOCART scores of 70 to 87 have been recorded from more than 20,000 implantations. The 2025 wrist study confirmed that clinically superior cartilage quality ratings — Outerbridge median 1.5 versus 3.0 and ICRS 1 versus 3 in controls (p<0.01) — are achievable even within the confined anatomy of a small joint. A 2024 Bulgarian knee series (n=17, mean age 31 years) added Lysholm and IKDC improvements sustained at twelve months. Ex vivo testing has since confirmed active cell migration into the scaffold, providing mechanistic grounding for what these clinical scores measure — though laboratory findings of this kind are not a direct substitute for clinical outcome data.

The NanoACi combination — ChondroFiller alongside autologous cartilage micrografts and platelet-rich fibrin — draws on these individually evidenced components. The complete three-part protocol has not yet been tested in a randomised trial; the rationale for combining the three is evidence-informed, but verification of their interaction as a unit remains outstanding.

Finding a specialist who offers the injection pathway

The preceding sections trace a distinction that eventually resolves into a practical question: is the injection pathway appropriate here, for this joint, this degree of wear, and this treatment history? That determination is not one a patient can make alone. Defect size, the integrity of surrounding cartilage, the degree of pre-existing degeneration, and prior treatments all weigh on the answer. Where the injection route does fit — delivered as an ultrasound-guided outpatient procedure, without theatre admission or general anaesthetic — it offers a biologically active scaffold that works through a fundamentally different logic from surgical repair. That difference in logic is also a difference in who qualifies. Neither pathway is universal, and both have defined ceilings.

Search MSK lists specialists across the UK who offer ChondroFiller and related injectable cartilage treatments — filter by region and specialty to find a practitioner near you who can assess whether this pathway is the right next step.